Cymabay Therapeutics Stock News

NEWARK, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative thera

NEWARK, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need, today announced that it has commenced an underwritten public offering of its common stock and pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by CymaBay. CymaBay intends to grant the underwriters a 30-day option to purchase up to an aggregate of an additional 15% of the number of shares of its common stock offered in the public offering (including shares underlying the pre-funded warrants). The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. CymaBay anticipates using the net proceeds from the offering to fund ongoing development of seladelpar and for working capital and general corporate purposes.

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) SVB Leerink upped their FY2021 earnings estimates for CymaBay Therapeutics in a research report issued to clients and investors on Thursday, November 11th. SVB Leerink analyst T. Smith now expects that the biopharmaceutical company will post earnings of ($1.27) per share for the year, up from their prior estimate of []

NEWARK, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that results of analyses from two clinical studies of seladelpar were delivered during The Liver Meeting Digital Experience 2021 (TLMdX) of the American Association for the Study of Liver Diseases (AASLD).

10 penny stocks to watch this week. The post 10 Top Penny Stocks To Watch With Potential Biotech Catalysts This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.co

Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at multiple conferences. Among the

Vanguard Group Inc. cut its holdings in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY) by 10.0% during the second quarter, Holdings Channel.com reports. The institutional investor owned 3,326,782 shares of the biopharmaceutical companys stock after selling 367,636 shares during the period. Vanguard Group Inc.s holdings in CymaBay Therapeutics were worth $14,505,000 as of its most recent []

CymaBay Therapeutics, Inc. (CBAY) CEO Sujal Shah on Q2 2021 Results - Earnings Call Transcript

CymaBay Therapeutics Inc. (CBAY) delivered earnings and revenue surprises of -13.79% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for

The broader market looks expensive, but these penny stocks provide low-cost opportunities for considerable upside according to analysts. The post 7 Penny Stocks With the Potential to 10X in 2022 appea

CymaBay Therapeutics, Inc. (CBAY) CEO Sujal Shah on Q2 2021 Results - Earnings Call Transcript

Secured up to $100 million of additional development funding through a non-dilutive financing transaction with Abingworth

CymaBay Therapeutics Inc (NASDAQ: CBAY) has received $100 million in non-dilutive financing from Abingworth to fund the Phase 3 development program for seladelpar in primary biliary cholangitis (